K-CAB Achieves Over 80% Eradication Rate
in All Dosage Groups
The clinical trial results for HK Innoen’s new gastroesophageal reflux disease drug “K-CAB” (active ingredient: tegoprazan) in eradicating Helicobacter pylori have been released, opening up the possibility of replacing existing proton pump inhibitor (PPI) drugs.
According to HK Innoen on October 15, these research results were presented at the 2025 United European Gastroenterology Week (UEGW), Europe’s largest gastroenterology conference, held in Berlin, Germany from October 4 to 7 (local time).
On the 4th of this month, the research team presented the clinical results of K-CAB Helicobacter eradication at the 2025 European Society of Gastroenterology conference. HK Innoen
This clinical trial was conducted on 382 domestic patients who tested positive for Helicobacter pylori. The study compared the safety and efficacy of a standard triple therapy containing the P-CAB (potassium-competitive acid blocker) drug K-CAB tablet (tegoprazan), amoxicillin, and clarithromycin, with a standard triple therapy containing the PPI drug lansoprazole, amoxicillin, and clarithromycin. Both regimens were administered for 14 days.
The clinical results showed that the eradication rates for the K-CAB 50mg and 100mg groups were 85.95% and 85.48%, respectively, surpassing the 78.74% eradication rate of the lansoprazole 30mg group and demonstrating non-inferiority (mITT analysis group). Notably, K-CAB achieved an eradication rate of over 80% in all dosage groups, confirming its potential as a first-line treatment for Helicobacter pylori eradication.
The current standard triple therapy for first-line Helicobacter pylori eradication involves taking a standard dose of a PPI drug, 1g of the antibiotic amoxicillin, and 500mg of clarithromycin twice daily. According to the “Revised Evidence-Based Clinical Practice Guidelines for the Treatment of Helicobacter pylori Infection in Koreans” published in 2020, an eradication rate of at least 80% is required for a regimen to be recommended as a first-line therapy.
In addition to the domestic clinical trial results for Helicobacter pylori eradication, the conference also featured results from a global investigator-initiated clinical trial of K-CAB conducted in Latin America. Latin America is one of the key markets for K-CAB, and HK Innoen plans to accelerate its global market expansion based on local data.
An HK Innoen representative stated, “These clinical results demonstrate that K-CAB can replace existing PPI drugs as a first-line treatment for Helicobacter pylori eradication. We will continue to strengthen K-CAB’s position in both domestic and international markets through various research efforts.”
K-CAB, Korea’s 30th new drug, has recorded a cumulative prescription amount of 810.1 billion won from its domestic launch in March 2019 through the first half of 2025.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
